The antibiotics market is expected to reach USD 57.0 billion by 2024. Rising prevalence of infectious diseases is contributing to the market growth, especially in developing regions such as Asia-Pacific. However, raising capital for companies active in this field has been difficult for the past few years. Thus, Venture Valuation has collected some important facts, … Continue reading Whitepaper: Focus on the Antibiotics Market
Last month, CEO of Venture Valuation, Dr Patrik Frei, delivered a live webinar titled ‘Valuation of Life Sciences Start-up’ to healthcare alumni of Harvard Business School You can watch the webinar here. Due to a large number of questions from participants, not all of them could be answered during the event. In this post, we … Continue reading Valuation of Life Sciences Start-up – Questions and Answers
The topic if this year’s evening event at JPM in San Francisco co-organized by BaselArea.swiss Economic Promotion, KPMG and Venture Valuation was Designing The Future in Life Sciences – A Discussion About (Human) Capital & Innovation. How will life sciences look like in – let’s say – 2030? What are sustainable and future business models for biotech … Continue reading Panel at JPM January 2017 – Future of Life Sciences
Bilan: 20 most influential people in the Swiss Life Sciences Industry French (PDF) – 8 pages – 125kb
Press release in “Depeche du Midi” (Toulouse, France) mentioning Venture Valuation French (PDF) – 1 pages – 209kb
Article on Venture Valuation published in Bilanz, edition April 2002 German (PDF) – 1 pages – 28kb
Titlestory in Venture Capital/Going Public 3/ February 2002 German (PDF) – 4 pages – 690kb
Report on Venture Valuation published in BOOM 9/2001, November 2001 German (PDF) – 2 pages – 110kb
